Evaluation of an automated closed fluid management device for processing expanded cytokine-induced killer cells to use in immunotherapy programs for cancer

Transfusion

Volumn 48, Issue 4, 2008, Pages 629-639

  Giancola, Raffaella ^a,b   Olioso, Paola ^a   Di Riti, Maria ^a   Capone, Anita ^a   Contento, Alessandro ^a   Pompetti, Franca ^a   Iacone, Antonio ^a  

^a Ospedale Reg Spirito Santo   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC ANTIBODY; DIMETHYL SULFOXIDE;

ADOPTIVE IMMUNOTHERAPY; ADULT; APOPTOSIS; ARTICLE; AUTOMATION; CELL EXPANSION; CELL MANIPULATION; CELL STRAIN K 562; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; CRYOPRESERVATION; CYTOTOXICITY; DAUDI CELL; DEVICE; FEMALE; HEALTH PROGRAM; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; KILLER CELL; MALE; MEDICAL INSTRUMENTATION; NATURAL KILLER CELL; QUALITY CONTROL;

ADULT; APOPTOSIS; CELL PROLIFERATION; CELL SURVIVAL; CYTOKINES; CYTOTOXICITY TESTS, IMMUNOLOGIC; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOTHERAPY, ADOPTIVE; K562 CELLS; KILLER CELLS; MALE; MIDDLE AGED; NEOPLASMS;

EID: 41149160955     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2007.01587.x     Document Type: Article

References (32)

1. Ljungman P, Urbano-Ispizua A, Cavazza-Calvo M, Demirer T, Dini G, Einsele H, Gratwohl A, Madrigal A, Niederwieser D, Passweg J, Rocha V, Saccardi R, Schouten H, Schmitz N, Socie G, Sureda A, Apperley J European Group for Blood and Marrow. Allogeneic and autologous transplantation for haematological disease, solid tumors and immune disorders; definition and current practice in Europe. Bone Marrow 2006 37 : 439 49.
2. Oliansky DM, Rizzo JD, Aplan PD, Arceci RJ, Leone L, Ravindranath Y, Sanders JE, Smith FO 3rd, Wilmot F, McCarthy PL Jr, Hahn T. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myeloid leukemia in children: an evidence based review. Biol Blood Marrow Transplant 2007 13 : 1 25.
3. Tallman MS, Gilliland DG, Rowe JM. Drug therapy for acute myeloid leukemia. Blood 2005 106 : 1154 63.
4. Litzow MR. Progress strategies for patients with relapsed and refractory acute myeloid leukemia. Curr Opin Hematol 2007 14 : 130 7.
5. Kolb HJ, Schmidt C, Barret AJ, Schendel DJ. Graft versus leukemia reaction in allogeneic chimeras. Blood 2004 103 : 767 76.
6. Levine JE, Braun T, Penza SL, Beatty P, Cornetta K, Martino R, Drobyski WR, Barrett AJ, Porter DL, Giralt S, Leis J, Holmes HE, Johnson M, Horowitz M, Collins RH Jr. Prospective trial of chemotherapy and donor lymphocyte for relapse of advanced myeloid malignancies after allogeneic stem cell transplantation. J Clin Oncol 2002 20 : 405 12.
7. Vollmer M, Li L, Schmitt A, Greiner J, Reinhardt P, Ringhoffer M, Wiesneth M, Döhner H, Schmitt M. Expression of human leukocyte antigens and costimulatory molecules on blasts of patients with acute myeloid leukemia. Br J Hematol 2003 54 : 933 43.
8. Porter DI, Antin JH. Donor leukocytes infusions in myeloid malignancies: new strategies. Best Pract Res Clin Haematol 2006 19 : 737 55.
9. Blair A, Goulden NJ, Libri NA, Oakhill A, Pamphilon DH. Immunotherapeutic strategies in acute lymphoblastic leukemia relapsing after stem cell transplantation. Blood Rev 2005 19 : 289 300.
10. Nijmeijer BA, van Schie ML, Verzaal P, Willemze R, Falkenburg JH. Response to donor lymphocyte infusion for acute lymphoblastic leukemia may be determined by both qualitative and quantitative limitations of antileukemic T-cell responses as observed in an animal model for human leukemia. Exp Hematol 2005 33 : 1172 81.
11. Mackall CL, Fleisher TA, Brown MR, Andrich MP, Chen CC, Feuerstein IM, Magrath IT, Wexler LH, Dimitrov DS, Gress RE. Distinctions between CD8+ and CD4+ T-cell regenerative pathways result in prolonged T-cell subset imbalance after intensive chemotherapy. Blood 1997 89 : 3700 7.
12. Mackall CL. T-cell immunodeficiency following cytotoxic antineoplastic therapy: a review. Stem Cells 2000 18 : 10 8.
13. Alvarnas JC, Linn YC, Hope EG, Negrin RS. Expansion of cytotoxic CD3+CD56+ cells from peripheral blood progenitor cells of patients undergoing autologous stem cell transplantation. Biol Blood Marrow Transplant 2001 7 : 216 22.
14. Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG, Weissman IL. Use of SCID mouse/human lymphoma model to evaluate cytokine induced killer cells with potent antitumor cell activity. J Exp Med 1991 174 : 139 49.
15. Mehta BA, Schmidt-Wolf IG, Weismann IL, Negrin RS. Two pathways of exocytosis of cytoplasmic granule contents and target cell killing by cytokine induced CD3+CD56+ killer cells. Blood 1995 86 : 3493 9.
16. Schmidt RE, Murray C, Daley JF, Schlossman SF, Ritz J. A subset of natural killer cells in peripheral blood displays a mature T cell phenotype. J Exp Med 1986 164 : 351 6.
17. Lu PH, Negrin RS. A novel population of expanded human CD3+CD56+ cells derived from T cells with a potent antitumor activity in mice with severe combined immunodeficiency. J Immunol 1994 153 : 1687 96.
18. Verneris RM, Karami M, Baker J, Jayaswal A, Negrin RS. Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. Blood 2004 103 : 3065 72.
19. Hoyle C, Bangs CD, Chang P, Kamel O, Mehta B, Negrin RS. Expansion of Philadelphia chromosome negative CD3+CD56+ cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice. Blood 1998 92 : 3318 27.
20. Lemarie C, Calmels B, Malenfant C, Arneodo V, Blaise D, Viret F, Bouabdallah R, Ladaique P, Viens P, Chabannon C. Clinical experience with the delivery of thawed and washed autologous blood cells, with an automated closed fluid fluid management device: Cytomate. Transfusion 2005 45 : 737 42.
21. Calmels B, Houze P, Hengesse JC, Ducrot T, Malenfant C, Chabannon C. Preclinical evaluation of an automated closed fluid management device: Cytomate for washing out DMSO from hemopoietic stem cell grafts after thawing. Bone Marrow Transplant 2003 31 : 823 8.
22. Pende D, Rivera P, Marcenaro S, Chang CC, Biassoni R, Kubin M, Cosman D, Moretta L, Moretta A. Major histocompatibility complex class I-related chain a and UL-16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res 2002 62 : 6178 86.
23. Osada T, Clay TM, Woo CY, Morse MA, Lyerly K. Dendritic cell based immunotherapy. Int Rev Immunol 2006 25 : 377 413.
24. Amrolia PJ, Muccioli-Casadei G, Huls H, Adams S, Durett A, Gee A, Yvon E, Weiss H, Cobbold M, Gaspar HB, Rooney C, Kuehnle I, Ghetie V, Schindler J, Krance R, Heslop HE, Veys P, Vitetta E, Brenner MK. Adoptive immunotherapy with allodepleted donor T cells improves immune reconstitution after haploidentical stem cell transplantation. Blood 2006 108 : 1797 808.
25. Hernandez-Pigeon H, Jean C, Charruyer A, Haure MJ, Titeux M, Tonasso L, Quillet-Mary A, Baudouin C, Charveron M, Laurent G. Manufacturing of gene modified cytotoxic T lymphocytes for autologous cellular therapy for lymphoma. Cytotherapy 2006 8 : 105 17.
26. Directive 2005/28 EC. Off J Eur Commun 2005 L 91/13-19.
27. McKenna D Jr, Kadidlo D, Sumstad D, McCullough J. Developmental and operation of quality assurance system for deviations from standard operating procedures in a clinical cell therapy laboratory. Cytotherapy 2003 5 : 314 22.
28. Gajic A, Hermann R, Salzberg M. The international quality requirements for the conduct of clinical studies and the challenges for study centers to implement them. Ann Oncol 2004 15 : 1305 9.
29. Verneris MR, Ito M, Baker J, Arshi A, Negrin RS, Shizuru JA. Engineering hematopoietic graft: purified allogeneic hematopoietic stem cells plus expanded CD8+ NK-T cells in the treatment of lymphoma. Biol Blood Marrow Transplant 2001 7 : 532 42.
30. Leemhuis T, Wells S, Scheffold C, Edinger M, Negrin RS. A phase I trial of autologous cytokine induced killer cells for the treatment of relapsed Hodgkin's disease and non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 2005 11 : 181 7.
31. Nowbakht P, Ionescu MC, Rohner A, Kalberer CP, Rossy E, Mori L, Cosman D, De Libero G, Wodnar-Filipowicz A. Ligands for natural killer cells activating receptors are expressed upon the maturation of normal myelomonocytic cells but at low levels in acute myeloid leukemias. Blood 2005 105 : 3615 22.
32. Sutherland CL, Rabinovich B, Chanlupny NJ, Brawand P, Miller R, Cosman D. ULPBs, human ligands of the NKG2D receptor, stimulate tumor immunity with enhancement by IL-15. Blood 2006 108 : 1313 9.